Roche to Halt Lung Cancer Trial After Results Miss Goals
By Adria Calatayud
Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after it failed to meet the trial's primary efficacy goals.
The Swiss pharmaceutical company said Thursday that its investigational tiragolumab drug in combination with its cancer immunotherapy Tecentriq and chemotherapy didn't meet the trial's objectives of progression-free survival and overall survival at its first interim analysis. Tiragolumab is thought to act as an amplifier of the body's immune response to cancer with other cancer drugs, it added.
The drug combination showed reduced efficacy compared to the comparator arm, Roche said. The trial compared tiragolumab, Tecentriq and chemotherapy against Merck's Keytruda and chemotherapy.
"These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer," Roche Chief Medical Officer and Head of Global Product Development Levi Garraway said.
Safety data were consistent with previous studies, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 04, 2024 01:35 ET (05:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks